Biogen Inc. (BIIB.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
6,514.57-141.43 (-2.12%)
At close: 9:00AM CDT
| Previous close | 6,656.00 |
| Open | 6,514.57 |
| Bid | 6,500.00 x 100 |
| Ask | 0.00 x 100 |
| Day's range | 6,514.57 - 6,514.57 |
| 52-week range | 4,766.00 - 8,700.00 |
| Volume | 47 |
| Avg. volume | 1,193 |
| Market cap | 980.801B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 25.85 |
| EPS (TTM) | 252.04 |
| Earnings date | 19 Oct 2021 - 25 Oct 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Biogen Defends Controversial Alzheimer's Drug as FDA Calls for Probe
Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its...
- Motley Fool
Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
BIIB earnings call for the period ending June 30, 2021.
- Yahoo Finance Video
AT&T, Crocs, Biogen top Q2 estimates, Didi shares dip as China regulatory woes persist
Myles Udland, Brian Sozzi, and Julie Hyman breakdown more Q2 earnings, which include: AT&T stock rising as the company topped estimates due to a push from wireless subscriber additions, Crocs beating earnings as sales growth accelerates from continued customer demand, Didi experiencing more scrutiny as China weighs serious penalties, and Biogen reporting strong Q2 earnings despite criticism of its new Alzheimer’s drug.
© 2021 Verizon Media. All rights reserved.
